Slow Parkinson progression with vutiglabridin
- Trial ID
- NCT06329141
- Official Title
- A Randomized, Double-Blind, Placebo-Controlled, Parallel Groups, Phase 2a Clinical Trial to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease Patients
- Goal
- Slow Parkinson progression with vutiglabridin
- Phase
- PHASE2
- Status
- RECRUITING
- Sponsor
- Glaceum
- Study Type
- INTERVENTIONAL
- Enrollment
- 90 participants
- Conditions
- Parkinson Disease
- Interventions
- Vutiglabridin, Placebo
Plain-Language Summary
The goal is to see whether vutiglabridin can protect dopamine-producing neurons and slow early Parkinson's progression, helping people keep function after a recent diagnosis. Participants are randomly given oral vutiglabridin or placebo, in a double-blind design; vutiglabridin is an experimental drug thought to boost cellular energy and reduce oxidative stress in neurons, aiming to slow dopamine loss rather than replace dopamine the way levodopa does. The trial is recruiting adults 40 to 75 who were diagnosed within the last two years, have mild disease (Hoehn-Yahr stage 2 or less) with PET-confirmed reduced dopamine transporter, and who are not on long-term levodopa or other excluded medications or major medical conditions.
Locations
- Hallym University Medical Center, Anyang-si, Gyeonggi-do, South Korea
- The Catholic University of Korea Uijeongbu St.Marys Hostpial, Uijeongbu-si, Gyeonggi-do, South Korea
- Inje University Busan Paik Hospital, Busan, South Korea
- Inje University Sanggye Paik Hospital, Seoul, South Korea
- KyungHee University Medical Center, Seoul, South Korea
- Severance Hospital, Seoul, South Korea
- Samsung Medical Center, Seoul, South Korea
- The Catholic University of Korea, Seoul, South Korea
- Korea University Guro Hospital, Seoul, South Korea
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Vutiglabridin. The goal is to see whether vutiglabridin can protect dopamine-producing neurons and slow early Parkinson's progression, helping people keep function after a recent diagnosis. Participants are randomly given oral vutiglabridin or placebo, in a double-blind design; vutiglabridin is an experimental drug thought to boost cellular energy and reduce oxidative stress in neurons, aiming to slow dopamine loss rather than replace dopamine the way levodopa does. The trial is recruiting adults 40 to 75 who were diagnosed within the last two years, have mild disease (Hoehn-Yahr stage 2 or less) with PET-confirmed reduced dopamine transporter, and who are not on long-term levodopa or other excluded medications or major medical conditions.
- Who can participate?
- Participants must be between 40 Years and 75 Years.
- Where is this trial located?
- This trial is recruiting at 9 locations.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This Phase 2 trial is estimated to last approximately 1 year and 5 months.